Edgewise Therapeutics Inc.

6.01+0.1900+3.26%Vol 162.33K1Y Perf -42.43%
Oct 4th, 2023 16:00 DELAYED
BID5.84 ASK6.30
Open5.98 Previous Close5.82
Pre-Market- After-Market6.18
 - -  0.17 2.83%
Target Price
23.80 
Analyst Rating
Strong Buy 1.20
Potential %
296.01 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
8.68 
Earnings Rating
Market Cap381.39M 
Earnings Date
2nd Nov 2023
Alpha-0.04 Standard Deviation0.15
Beta-0.22 

Today's Price Range

5.856.13

52W Range

5.4911.48

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.59%
1 Month
-9.77%
3 Months
-22.81%
6 Months
-6.43%
1 Year
-42.43%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EWTX6.010.19003.26
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
27.40
27.80
0.01
0.01
-
Leverage Ratio 1.00
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.41-0.3417.07
Q01 2023-0.37-0.362.70
Q04 2022-0.36-0.3113.89
Q03 2022-0.36-0.345.56
Q02 2022-0.34-0.325.88
Q01 2022-0.29-0.30-3.45
Q04 2021-0.28-0.267.14
Q03 2021-0.22-0.26-18.18
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date2nd Nov 2023
Estimated EPS Next Report-0.40
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume162.33K
Shares Outstanding63.46K
Shares Float28.81M
Trades Count2.43K
Dollar Volume976.27K
Avg. Volume139.79K
Avg. Weekly Volume119.37K
Avg. Monthly Volume134.30K
Avg. Quarterly Volume165.70K

Edgewise Therapeutics Inc. (NASDAQ: EWTX) stock closed at 5.82 per share at the end of the most recent trading day (a 0.87% change compared to the prior day closing price) with a volume of 164.08K shares and market capitalization of 381.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. Edgewise Therapeutics Inc. CEO is Kevin Koch.

The one-year performance of Edgewise Therapeutics Inc. stock is -42.43%, while year-to-date (YTD) performance is -34.9%. EWTX stock has a five-year performance of %. Its 52-week range is between 5.49 and 11.48, which gives EWTX stock a 52-week price range ratio of 8.68%

Edgewise Therapeutics Inc. currently has a PE ratio of -7.90, a price-to-book (PB) ratio of 1.65, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -18.14%, a ROC of -19.14% and a ROE of -18.84%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Edgewise Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Edgewise Therapeutics Inc.’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Edgewise Therapeutics Inc. is Strong Buy (1.2), with a target price of $23.8, which is +296.01% compared to the current price. The earnings rating for Edgewise Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Edgewise Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Edgewise Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 52.22, ATR14 : 0.38, CCI20 : -117.13, Chaikin Money Flow : -0.06, MACD : -0.25, Money Flow Index : 30.89, ROC : -9.35, RSI : 37.06, STOCH (14,3) : 22.76, STOCH RSI : 0.43, UO : 50.69, Williams %R : -77.24), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Edgewise Therapeutics Inc. in the last 12-months were: Alan J. Russell (Sold 0 shares of value $0 ), Alan J. Russell (Sold 1 602 shares of value $14 258 ), Carruthers R Michael (Option Exercise at a value of $7 100), Derakhshan Behrad (Sold 0 shares of value $0 ), Derakhshan Behrad (Sold 1 747 shares of value $15 548 ), Joanne M. .Donovan (Sold 0 shares of value $0 ), Joanne M. .Donovan (Sold 3 254 shares of value $28 961 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
4 (66.67 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
1 (16.67 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (16.67 %)
Summary RatingStrong Buy
1.20
Strong Buy
1.20
Moderate Buy
1.83

Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

CEO: Kevin Koch

Telephone: +1 303 735-8373

Address: 3415 Colorado Avenue, Boulder 80303, CO, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

52%48%

Bearish Bullish

56%44%

 

TipRanks News for EWTX

Mon, 14 Aug 2023 02:25 GMT Edgewise Therapeutics (EWTX) Receives a Buy from Truist Financial

- TipRanks. All rights reserved.

News

Stocktwits